Seattle-based biotech start-up Lumen Bioscience increased a $ 30 million Collection C expansion and revealed a number of management updates.
WestRiver Group led the most up to date funding round, bringing the business &# 8217; s complete capital raised to $ 186 8 million.
The new investment will aid Lumen increase its pipeline of orally delivered biologic drugs made from genetically crafted spirulina, a sort of turquoise algae.
Lumen &# 8217; s modern technology platform makes it possible for restorative proteins– traditionally injected or instilled– to be generated and provided by mouth in an edible, low-cost type.
The 110 -person company is targeting illness that act in or stem from the intestinal tract. It lately reported encouraging Stage 2 arise from LMN- 201, Lumen’s lead candidate for recurrent C. difficile infection.
The business also revealed that Jeff Raikes , previous Microsoft head of state and Gates Structure CEO, signed up with Lumen’s board as an independent director.
Other personnel updates:
- Erik Anderson , owner and CEO of WestRiver Group, was elected vice chairman of the board.
- Interior promos consist of Nhi Khuong to EVP and Kole Krieger to SVP, while Dr. David Saunders, a retired united state Army colonel and medical trialist, joined the medical growth team.
The company has expanded its workforce by nearly 40 % given that 2023 and opened up a second production center.
Lumen is led by chief executive officer Brian Finrow , a previous senior vice president at Adaptive Biotechnologies, and Chief Scientific Research Police Officer Jim Roberts , the former head of basic sciences at the Fred Hutchinson Cancer Cells Study Institute. They co-founded the start-up in 2017